| 臺大學術典藏 |
2021-09-02T00:04:15Z |
Analysis of Racetrack-Coupled Mach Zehnder Interferometer for High-Speed Communication
|
Ku K.-N;Chang P.-C;Wang C.-C;Lin C.-Y;Hsu C.-H;Chen T.-H;Huang C.-Y;Wun S.-J;Lee C.-S;Chen S.-C;Lee M.-C;Lin C.-C;Wu C.-I.; Ku K.-N; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A Frequency Digital Pre-Distortion Compensation Method for FMCW LiDAR System
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:04:14Z |
A frequency digital pre-distortion compensation method for FMCW LiDAR system
|
Chen T.-H;Huang C.-Y;Shia T.K;Wun S.-J;Hsu C.-H;Ku K.-N;Lee C.-S;Lin C.-Y;Chang P.-C;Wang C.-C;Chen S.-C;Lin C.-C;Wu C.-I.; Chen T.-H; CHIH-I WU et al. |
| 臺大學術典藏 |
2021-09-02T00:03:46Z |
Near-CAZAC Preamble Sequences for Initial Synchronization in Spectrally Compact OFDM
|
Lin C.-C;Chen W.-C;Chung C.-D.; Lin C.-C; Chen W.-C; Chung C.-D.; CHAR-DIR CHUNG |
| 臺大學術典藏 |
2021-09-02T00:03:43Z |
Simulation Model of Multiple Oxide-Aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cjo Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cjo Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; CHAO-HSIN WU |
| 臺大學術典藏 |
2021-09-02T00:03:43Z |
Simulation model of multiple oxide-aperture VCSEL
|
Hsu S.-C;Huang Y.-M;Cho Y.-Y;Peng C.-Y;Wu C.-H;Lin G.-R;Kuo H.-C;Lin C.-C.; Hsu S.-C; Huang Y.-M; Cho Y.-Y; Peng C.-Y; Wu C.-H; Lin G.-R; Kuo H.-C; Lin C.-C.; CHAO-HSIN WU |
| 臺大學術典藏 |
2021-09-01T02:02:30Z |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer
|
Lin C.-C.; Hsu C.-H.; Chen J.; Tsai T.-C.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:26Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C.-H.; ANN-LII CHENG; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:11Z |
Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: An effective regimen with low toxicity
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Chen J.; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Wang H.-P.; Lee J.-M.; Yeh K.-H.; Yang C.-H.; Lin J.-T.; ANN-LII CHENG; Lee Y.-C. |
| 臺大學術典藏 |
2021-09-01T02:02:09Z |
Phase II Trial of Weekly Paclitaxel, Cisplatin Plus Infusional High Dose 5-Fluorouracil and Leucovorin for Metastatic Urothelial Carcinoma
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; ANN-LII CHENG; Vogelzang N.J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T02:02:08Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Lin C.-C.; ANN-LII CHENG; Hsu C.-H.; Lu Y.-S.; Hsu C.; Yeh K.-H.; Wu C.-Y.; Huang C.-S.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:07Z |
Arsenic trioxide in patients with hepatocellular carcinoma: A phase II trial
|
Lin C.-C.; Hsu C.; Hsu C.-H.; Hsu W.-L.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
Prognostic Factors for Metastatic Urothelial Carcinoma Treated with Cisplatin and 5-Fluorouracil-Based Regimens
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:33Z |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study
|
Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; Tsai Y.-C.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma
|
Lin C.-C.; Yeh K.-H.; Yang C.-H.; Hsu C.; Tsai Y.-C.; Hsu W.-L.; ANN-LII CHENG; Hsu C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:32Z |
Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: In vitro combined effects and a Phase II trial
|
Lin C.-C.; Hsu C.-H.; Hour T.-C.; ANN-LII CHENG; Huang C.-Y.; Huang K.-H.; Chen J.; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:54:29Z |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment
|
Lin Z.-Z.; Hsu C.; Chang Y.-C.; Yu C.-J.; Hsu C.-H.; Lin C.-C.; ANN-LII CHENG; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:27Z |
Acute encephalopathy following arsenic trioxide for metastatic urothelial carcinoma
|
Lin C.-C.; Pu Y.-S.; Hsu C.-H.; Keng H.-Y.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:26Z |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
|
Hsu C.; Kuo S.-H.; Hu F.-C.; ANN-LII CHENG; Shih J.-Y.; Yu C.-J.; Lin C.-C.; Huang T.-C.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
National Center of Excellence for Clinical Trials and Research at National Taiwan University Hospital
|
Lin C.-C.; Yang C.-H.; ANN-LII CHENG; Chan W.-K.; Ho N.-N. |
| 臺大學術典藏 |
2021-09-01T01:54:19Z |
Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer
|
Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; Tsai Y.-C.; Hsu F.-M.; Huang K.-H.; ANN-LII CHENG; Pu Y.-S. |
| 臺大學術典藏 |
2021-09-01T01:53:45Z |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy
|
Chen W.-W.; Lin C.-C.; Huang T.-C.; ANN-LII CHENG; Yeh K.-H.; Hsu C.-H. |
| 臺大學術典藏 |
2021-08-31T06:42:27Z |
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
|
Ghamande S.; Lin C.-C.; Cho D.C.; Shapiro G.I.; Kwak E.L.; Silverman M.H.; Tseng Y.; Kuo M.-W.; Mach W.B.; Hsu S.-C.; Coleman T.; Yang J.C.-H.; ANN-LII CHENG; Ghalib M.H.; Chuadhary I.; Goel S. |
| 臺大學術典藏 |
2021-08-31T06:42:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.; Su W.-C.; Yen C.-J.; Hsu C.-H.; Su W.-P.; Yeh K.-H.; Lu Y.-S.; ANN-LII CHENG; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
